RxDoctor Payments Data

Bradley Wrubel, MD

Neurology · Berkeley, CANPI 1487760997

Payments from drug & device makers

$1,843in general payments, 2019–2025

Across 26 payments — averaging $70.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428
  • SK Life Science, Inc.$237
  • UCB, Inc.$203
  • Novartis$168
  • AbbVie$142
  • Livanova USA, Inc.$122
  • plus $543 from 6 others

What the payments were for

  • Food & beverage$1,839100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,843 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$207,606
Medicare patients
656
Services billed
4,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5028$276,016
Nurtec OdtRimegepant Sulfate25$42,512
Emgality PenGalcanezumab-Gnlm40$33,812
RytaryCarbidopa/Levodopa15$26,764
BriviactBrivaracetam12$16,740
Lacosamide48$11,882
Rasagiline Mesylate20$4,837
Carbidopa-LevodopaCarbidopa/Levodopa116$3,663
Gabapentin247$2,860
Levetiracetam95$2,506
Pyridostigmine Bromide29$2,360
Memantine Hcl78$2,165
Mycophenolate Mofetil13$1,355
Azathioprine16$1,249
Lamotrigine47$1,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$203$16,74012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →